Revolution Medicines priced a $2 billion concurrent stock and debt offering shortly after reporting Phase 3 top-line data for daraxonrasib, its RAS inhibitor for metastatic pancreatic ductal adenocarcinoma. The financing appears designed to capitalize on investor demand following the survival readout, which company materials say nearly doubled median overall survival versus chemotherapy. The follow-on is positioned as the largest public raise in biotech history, underscoring how quickly market access can open after late-stage efficacy signals. For companies with liver cancer, solid tumor, and RAS-driven oncology programs, the deal also highlights how the capital stack is re-accelerating around late-breaking datasets. Daraxonrasib’s Phase 3 results are the near-term catalyst; the company is expected to submit for regulatory review on a fast-track pathway. The offering’s timing suggests management is preparing for a rapid transition from Phase 3 execution to commercialization planning and confirmatory activities. Overall, the transaction signals continued risk appetite among investors for high-conviction oncology assets, particularly those tied to RAS pathway biology and backed by late-stage survival endpoints.